Sonata, Cardizem LA Paragraph IV Certifications Filed
This article was originally published in The Pink Sheet Daily
Executive Summary
Paragraph IV certification for Jones Pharma’s insomnia agent Sonata (zaleplon) filed June 21. New chemical exclusivity for the drug expired in 2004.
You may also be interested in...
King To End Agreement With Elan On Sonata Modified-Release Formulation
King is discontinuing efforts to develop a modified-release formulation of the insomnia agent Sonata (zaleplon)
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products